Daily Hong Kong Stock Market News Briefing (November 28, Thursday)

USHK News
2024.11.28 01:10

Individual Stock News

  1. REGINA MIRACLE (02199.HK): The interim performance revenue is approximately HKD 3.978 billion, a year-on-year increase of 12.2%, with a net profit of HKD 67.619 million, a year-on-year decrease of 36.7%.

  2. Kingkey Financial International (01468.HK): Announced interim results with a profit attributable to owners of HKD 6.806 million, a year-on-year decrease of 91.12%.

  3. Chengdu Expressway (01785.HK): Chengwenqiong Expressway Company signed a land acquisition and demolition agreement with the government of Wenjiang District.

  4. SINO BIOPHARM (01177.HK): The indication for Bemarituzumab injection combined with Anlotinib hydrochloride capsules for the treatment of endometrial cancer has been approved for market launch.

  5. CMS (00867.HK): The innovative drug GLP-1R/GCGR dual agonist CMS-D005 has received a clinical trial approval notice.

  6. Shengyang Group (08163.HK): Completed the issuance of convertible securities with a principal amount of HKD 101 million.

  7. Laikang Pharmaceutical-B (02105.HK) completed the placement of 17.636 million shares, raising approximately HKD 230 million.

  8. Hansoh Pharmaceutical (03692.HK): The fifth indication application for the new lung cancer drug "Amivantamab" has been submitted for market launch.

  9. JIUYUAN GENE (02566.HK): The share price is set at HKD 12.42, with the public offering being 675.83 times oversubscribed

Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.